Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC

Emergent Technologies, Inc. announced today that it has hired seasoned business development professional and immunology expert Gregory Frank, Ph.D. as President of Pure Protein, LLC, a leading developer of soluble HLA protein reagents for use in therapeutic and diagnostic applications; and Pure MHC, LLC, developer of a proprietary technology used to discover novel targets to treat infectious disease and cancer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Gregory D. Frank, Ph.D., President of Pure Protein, LLC and Pure MHC, LLC

Gregory’s comprehensive background in business development, drug discovery and development, and strong alliance management skills will help take Pure Protein and Pure MHC to the next level.

Austin, TX and Oklahoma City, OK (PRWEB) December 17, 2013

Emergent Technologies, Inc. a Texas-based innovation solutions company specializing in the commercialization of life and material science technologies; announced today that it has hired Gregory Daniel Frank, Ph.D. as President of Pure Protein, LLC and Pure MHC, LLC. Dr. Frank is a seasoned business development professional and immunology expert with vast experience sourcing, structuring, negotiating, and closing agreements for licensing, strategic alliances, and discovery and development services in the pharmaceutical industry.

“The recent forming of Pure MHC and the increasing number of partnership opportunities made the timing right to bring Dr. Frank on board,” said Thomas Harlan, CEO of Pure Protein, Pure MHC and Emergent Technologies, Inc., the innovation solutions company that funds and manages both companies. “Gregory’s comprehensive background in business development, drug discovery and development, and strong alliance management skills will help take Pure Protein and Pure MHC to the next level.”

“Thomas Harlan has a unique approach to building companies and creating value that is unparalleled in this industry. I’m excited to be part of his team,” said Gregory.

Dr. Frank most recently served as Director, Business Development at XBiotech USA, Inc. an Austin, TX based company developing novel antibody therapies, where he had sole responsibility for all aspects of partnering the company’s clinical and preclinical assets and for corporate development that included raising capital for ongoing operations, building a manufacturing facility, and conducting a Phase III trial. Previously, he spent 10 years at SRI International, Biosciences as Director, Business Development and Marketing where he was involved in business development and marketing for all aspects of SRI's business model, successfully growing basic research, drug discovery, and contract research (CRO) services and learning the intricacies of value creation. Dr. Frank earned his Ph.D. in Immunology from Stanford University School of Medicine and his B.A. in Biology from the University of California at Santa Cruz.

About Pure Protein

Pure Protein, LLC has developed and patented several soluble HLA protein reagents and uses of those reagents in therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Transplant Solutions, L.L.C., a subsidiary of Pure Protein, is using sHLA protein to develop multiple diagnostics, devices, and therapeutics to eliminate rejection in organ transplants. Pure Vaccine Solutions, L.L.C (PVS), another subsidiary of Pure Protein, is an immunology company focused on methods to discover MHC-based diagnostic and therapeutic targets specific to infectious diseases and cancers. Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information, visit http://www.pureproteinllc.com.

About Pure MHC

Pure MHC, LLC was formed as a single market facing entity uniting the complementary technologies of PVS and Receptor Logic Inc. Pure MHC uses proprietary technology to discover novel targets to treat infectious disease and cancer and then to drug those targets in multiple ways, in particular using its proprietary technology to generate T-cell receptor mimicking monoclonal antibodies to those novel targets. For more information visit http://www.puremhc.com.

About Emergent Technologies, Inc.

Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages,develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit http://www.emergenttechnologies.com.


Contact

  • Cameron Mackie
    Emergent Technologies, Inc.
    512 263 3232
    Email
Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn